Amgen (AMGN): FY26 Q1 earnings call, Apr 30, 2026

…of therapy like Repatha. These guidelines do not yet reflect the practice-changing VESALIUS-CV data, leaving a clear opportunity to further evolve clinical guidelines and quality…

…risk in both primary and secondary prevention. Physician response to our landmark VESALIUS-CV study has been strong with sustained increases in new-to-brand prescribing across cardiology…

…events. In March, a new prespecified subgroup analysis from the Phase III VESALIUS-CV trial was presented at the American College of Cardiology and simultaneously published…

…and a nominal 24% reduction in all-cause death. Taken together with the VESALIUS-CV data presented last fall, these findings reinforce the breadth and magnitude of…

…some of the news flow that we've seen new data from the VESALIUS-CV trial that we presented last November at the AHA meeting. And then…